RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

A federal judge threw out Amgen’s lawsuit against the state board empowered to set first-in-the-nation price ceilings on prescription drugs in Colorado, finding that the maker of arthritis medication ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

From today, the updated indication for TRIKAFTA is as follows: TRIKAFTA is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in ...

Vertex Pharmaceuticals (VRTX) is the second stock to buy for the Nasdaq 100 correction. The biotech stock offers stability ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

TRIKAFTA/KAFTRIO. For 2025, the company has projected total revenue between $11.75 billion and $12.0 billion.

The economy has been on shaky ground for a while, and President Trump's tariffs and trade wars could finally send it into a ...

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...

It markets several CF treatments, including TRIKAFTA/KAFTRIO, ALYFTREK, and ORKAMBI, and is also developing therapies for sickle cell disease, type 1 diabetes, and other conditions. The Boston ...